Welcome to Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
1. OncoQuest transferred its immunotherapy assets to OncoQuest Pharmaceuticals, Inc. (“OQP”) in return for convertible bonds and a corporate bond of OQP with a face value of Cdn$385 million. The OQP bonds will be exchanged into bonds of Canaria Bio M and are planned to be exchangeable ultimately into shares of Canaria Bio. OncoQuest issued an in-kind dividend of OQP bonds (face value Cdn$320 million) to its shareholders on January 14, 2022. Quest’s portion, fully diluted, is approximately KRW 129.1 billion face value of OQP bonds ($cdn 136M).
2. OncoVent has an estimated book value of Cdn$11.8 million. Quest has an 10.67 % direct ownership interest in OncoVent. Quest also has a 12% indirect interest through its ownership interest in OncoQuest. OncoQuest owns 29% of OncoVent.